159 related articles for article (PubMed ID: 8704739)
1. Effects of chronic octreotide treatment on GH secretory dynamics and tumor growth in rats bearing an ectopic somatotroph (GC) tumor.
Mounier F; Bluet-Pajot MT; Viollet C; Bertherat J; Timsit J; Tannenbaum GS; Epelbaum J
J Neuroendocrinol; 1995 Aug; 7(8):645-51. PubMed ID: 8704739
[TBL] [Abstract][Full Text] [Related]
2. Effects of neonatal administration of octreotide, a long-lasting somatostatin analogue, on growth hormone regulation in the adult rat.
Slama A; Bluet-Pajot MT; Mounier F; Videau C; Kordon C; Epelbaum J
Neuroendocrinology; 1996 Feb; 63(2):173-80. PubMed ID: 9053782
[TBL] [Abstract][Full Text] [Related]
3. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
4. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
5. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory control of growth hormone secretion by somatostatin in rat pituitary GC cells: sst(2) but not sst(1) receptors are coupled to inhibition of single-cell intracellular free calcium concentrations.
Cervia D; Petrucci C; Bluet-Pajot MT; Epelbaum J; Bagnoli P
Neuroendocrinology; 2002 Aug; 76(2):99-110. PubMed ID: 12169771
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucocorticoid treatment and acute passive immunization with growth hormone-releasing hormone and somatostatin antibodies on endogenous and stimulated growth hormone secretion in the male rat.
Miell J; Corder R; Miell PJ; McClean C; Gaillard RC
J Endocrinol; 1991 Oct; 131(1):75-86. PubMed ID: 1683888
[TBL] [Abstract][Full Text] [Related]
11. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.
Renner U; Brockmeier S; Strasburger CJ; Lange M; Schopohl J; Müller OA; von Werder K; Stalla GK
J Clin Endocrinol Metab; 1994 May; 78(5):1090-6. PubMed ID: 8175966
[TBL] [Abstract][Full Text] [Related]
14. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
[TBL] [Abstract][Full Text] [Related]
15. Chronic growth hormone (GH) hypersecretion induces reciprocal and reversible changes in mRNA levels from hypothalamic GH-releasing hormone and somatostatin neurons in the rat.
Bertherat J; Timsit J; Bluet-Pajot MT; Mercadier JJ; Gourdji D; Kordon C; Epelbaum J
J Clin Invest; 1993 Apr; 91(4):1783-91. PubMed ID: 8097209
[TBL] [Abstract][Full Text] [Related]
16. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.
Murray RD; Kim K; Ren SG; Chelly M; Umehara Y; Melmed S
J Clin Invest; 2004 Aug; 114(3):349-56. PubMed ID: 15286801
[TBL] [Abstract][Full Text] [Related]
17. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin.
Tannenbaum GS; Lapointe M; Gurd W; Finkelstein JA
Endocrinology; 1990 Dec; 127(6):3087-95. PubMed ID: 1979030
[TBL] [Abstract][Full Text] [Related]
19. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
20. Octreotide treatment suppresses malignant somatotrophic pituitary tumor cell growth in rats.
Kondo H; Takino H; Akino K; Yamasaki H; Yamaguchi Y; Ito M; Eguchi K
Oncol Rep; 2000; 7(5):965-9. PubMed ID: 10948323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
